Abstract:Objective To evaluate the efficacy of a tolterodine tartrate based combined drug therapy in the treatment of severe female urethral syndrome(FUS).Methods Twenty-three female US patients diagnosed with severe female urethral syndrome were recruited in this prospective 2-month clinical trial. The average course of patient's history was (40.7±11.6) months, ranging from 19 to 72 months. All 23 patients were observed with severe urination frequency(>30/day, >10/night), urination urgency, urination pain and frequent acute pelvic pain, along with psychological symptoms such as loss of faith in treatment, neuroticism, suicidal mentality, anxiety, etc. Among 23 patients, 3 patients had lost self-care ability, 1 patient had lost exercise ability, 2 patients had suicidal tendency, 1 patient had suicidal behavior. According to individual patient conditions and symptoms, combined drug therapies, including α-receptor blocker, estrogen, low addictive pain killer, anti-histamine drug, antidepressant drug and sedative drug were applied. Basic dosage of tolterodine tartrate is 2 mg bid, and dosages of other drugs were conventional. The treatment normally starts with α-receptor blocker and low addictive pain killer. Antidepressant drug and estrogen were applied to patients with strong psychological symptoms and abnormal estrogen level when the therapy started. All 15 patients were re-examined one week after the therapy. For patients observed with obvious improvements, the therapy remained the same. For patients with non-obvious improvements, more combined drugs would be applied based on the patient's conditions. For patients with severe symptoms or not responsive to the initial therapy, multi-drugs were combined in the beginning of the therapy. The trail went on for 2 months. Pre-treatment and post-treatment patient clinical symptoms(daily urination frequency, urination pain score and pelvic pain occurrences) were observed. Side effects were recorded.Results (1)Daily urination frequency was obviously lower after the 2-month trial. Frequencies were improved from (31.5±4.4) times per day for pre-treatment to (16.6±3.2) times per day for post-treatment. Pelvic pain occurrences were much less after the 2-month trial. Occurrences were reduced from (15.6±2.7) times per week for pre-treatment to (2.4±1.6) times per week for post-treatment. Both above results were statistically significant(P<0.01). (2)Urination pain scores lowered substantially from (6.8±1.1) for pre-treatment to (3.7±1.5) for post-treatment. Pelvic pain were eased much and quality of life scores(QOL) were substantially lowered from (5.8±0.6) for pre-treatment to (2.2±0.8) for post-treatment. The pre-treatment and post-treatment differences were statistically significant (P<0.01). (3)Psychological symptoms were substantially improved and suicidal tendencies were removed. (4)There was no obvious main complaint from all 15 patients. Considering the side effects influences might be masked by improved psychological conditions resulted from relieved symptoms, side effects of the therapy relies on further clinical studies.Conclusion A tolterodine tartrate based, patient-specific, combined drug therapy can quickly and effectively relieves the clinical symptoms of severe female urethral syndrome(SFUS), and improves quality of life and psychological conditions of the patients. The side effects are well tolerated.

The therapy effect of amitriptyline and dimethyl sulfoxide for interstitial cystitis—a clinical research

Application of Amitriptyline in the Treatment of Interstitial Cystitis

Treatment of Irritable Bowel Syndrome with Drotaverine Hydrochloride: A Multicentre Clinical Trial

The efficacy and safety of amitriptyline combined with sodium hyaluronate therapy for bladder pain syndrome(Report of 58 cases)

Clinical Observation on Heat Sensitive Moxibustion Combined with Abdominal Acupuncture Therapy and Kegel Exercise in Treating 28 Females' Stress Urinary Incontinence

Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome according to two criteria: does ESSIC criteria change the response rate?

Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review

Efifcacy of biofeedback and electrical stimulation in the treatment of non-ulcer interstitial cystitis/painful bladder syndrome

SF-36 quality of life in effectiveness ssessment for irritable bowel syndrome

[The Study of Diagnosis and Treatment of Interstitial Cystitis].

Clinical Efficacy of Submucosal Injection of Triamcinolone Acetonide in the Treatment of Type II/III Interstitial Cystitis/bladder Pain Syndrome

Intravesical instillation resiniferatoxin and hydrodistention for the treatment of interstitial cystitis

Efficacy and Safety Comparison of Pharmacotherapies for Interstitial Cystitis and Bladder Pain Syndrome: a Systematic Review and Bayesian Network Meta-Analysis

Effect of Bladder Perfusion with Sodium Hyaluronate Combined with Ultrashort Wave in Treatment of Non-Bacterial Cystitis

Efficacy of Frankincense and Myrrha in Treatment of Acute Interstitial Cystitis/Painful Bladder Syndrome

Clinical study on combined drug therapy of severe female urethral syndrome

Disease Correlation and Effects of Pelvic Floor Muscle Training on Tolterodine Based Treatment for Female Primary Overactive Bladder Syndrome

Comparative effectiveness and safety of intravesical instillation treatment of interstitial cystitis/bladder pain syndrome: a systematic review and network meta-analysis of randomized controlled trials

Treatment of female interstitial cystitis with bladder hydrodistention and heparin(report of 10 cases)

Efficacy assessment of bladder hydrodistension combined with drug intravesical instilla-tion for treatment of interstitial cystitis/bladder pain syndrome

Effects of electroacupuncture on refractory interstitial cystitis/bladder pain syndrome: A one-year follow-up case report